FY2022 · ended Dec 31, 2022 · Revenue $135,355, +85.2% YoY · Filed Apr 17, 2023
Endonovo Therapeutics, Inc. (ENDV) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2022, which ended Dec 31, 2022, it reported revenue of $135,355 and a net loss of $18.5 million. As of Sep 30, 2023 it held $0 in cash and investments and $7.1 million in total debt.
Revenue (TTM)
$255,723
+1699.9% vs year-ago TTM
Net income (TTM)
$-4.40M
-40.0% vs year-ago TTM
Operating cash flow (TTM)
$-629,904
+25.4% vs year-ago TTM
Free cash flow
$-2.54M
+11.9% vs prior year
EPS
—
Dividend per share
None
Shares outstanding
270.29M
+80.8% vs prior year
Net cash
$-7.09M
as of Sep 30, 2023
Operating margin
-1023.2%
FY 2023
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- ENDV (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Woodland Hills, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1528172
- Former names
- Hanover Portfolio Acquisitions, Inc. (until Jan 24, 2014)
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
FY 2019 Dec 31, 2019 |
FY 2018 Dec 31, 2018 |
|---|---|---|---|---|---|
| Revenue | $135,355 | $73,105 | $165,796 | $310,164 | $83,263 |
| Operating income | -$3.3M | -$2.2M | -$2.9M | -$3.8M | -$4.2M |
| Net income | -$18.5M | -$3.1M | -$395,584 | -$17.3M | -$6.4M |
| Operating cash flow | -$678,838 | -$986,584 | -$741,590 | -$2.5M | -$2.9M |
| Free cash flow | — | — | — | -$2.5M | -$2.9M |
| Total assets | $1.3M | $2.0M | $2.6M | $3.3M | $4.2M |
| Total liabilities | $33.5M | $17.8M | $17.0M | $23.8M | $15.6M |
| Stockholders' equity | -$32.2M | -$15.8M | -$14.4M | -$20.5M | -$11.4M |
| Cash and investments | $98 | — | — | — | — |
| Total debt | $7.2M | $7.3M | $6.8M | $6.9M | $8.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Jan 3, 2024 | Dec 29, 2023 |
| 10-Q/A | Amended quarterly report | Dec 29, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Dec 29, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Material agreement
|
Dec 4, 2023 | Dec 4, 2023 |
| 8-K |
Current report
Other events
|
Oct 12, 2023 | Oct 5, 2023 |
| 10-Q | Quarterly report | Aug 21, 2023 | Jun 30, 2023 |
All 502 Endonovo Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.